Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Opening Session Panel Discussion

Advertisement

Advertisement




Aug
05
Today In Oncology
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
AI-Based cfDNA Fragmentome Classifier May Improve Detection of HCC
Next-Generation Sequencing Uptake Remains Low Among Medicare Beneficiaries, Study Finds
U.S. News & World Report Announces 2026–2027 Best Cancer Hospitals
TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo